Cellerant to Present at the International Society for Stem Cell Research (ISSCR) 10th Annual Meeting in Japan

SAN CARLOS, Calif.--(BUSINESS WIRE)--

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that Cellerants President and CEO, Ram Mandalam, Ph.D., will be presenting at the International Society for Stem Cell Research (ISSCR) 10th Annual Meeting held June 13 16 in Yokohama, Japan.

Dr. Mandalam will be co-chairing a session Stem Cells and Cancer and will be giving a presentation, titled Antibodies Targeting Cancer Stem Cells in Hematological Malignancies, on Saturday, June 16 at 1:30 p.m. JST (Japan time). Dr. Mandalam will provide an overview of Cellerants cancer stem cell discovery approach and new data on its therapeutic antibodies demonstrating activity against acute myelogenous leukemia (AML) cancer stem cells.

Cellerant scientist, Anna Sedello, Ph.D. will also be presenting Poster #1144 titled Ex vivo-Generated Mouse Myeloid Progenitor Cells Mitigate Gastrointestinal Acute Radiation Syndrome when Administered up to 5 Days after Irradiation. These results demonstrate that cryopreserved, allogeneic myeloid progenitor cells from mice prevent death from lethal radiation doses known to cause death through hematopoietic and gastrointestinal injury. These results also show that myeloid progenitor cells are one of the most promising radiation countermeasures among all therapeutics currently under development with respect to efficacy, timing and practicality of administration. This work was carried out in collaboration with scientists at the Armed Forces Radiobiology Research Institute (AFFRI).

About Cellerants Cancer Stem Cell Antibody Program

Cellerant has developed an antibody program focused on tumor initiating cells, also known as cancer stem cells (CSCs) in leukemia and other hematological malignancies. These cancer stem cells are likely to be responsible for the relapse and resistance to current therapies for hematologic malignancies. Initially focused in AML, Cellerant has discovered novel antibody therapeutics with potent in vitro and in vivo efficacy characteristics targeting unique cancer stem cell antigens.

About Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerants lead product, CLT-008, is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a cancer stem cell (CSC) antibody discovery program focused on therapies for acute myelogenous leukemia, multiple myeloma and myelodysplastic syndrome.

For more information, visit: http://www.cellerant.com.

Excerpt from:
Cellerant to Present at the International Society for Stem Cell Research (ISSCR) 10th Annual Meeting in Japan